» Articles » PMID: 22802077

CellMiner: a Web-based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

Overview
Journal Cancer Res
Specialty Oncology
Date 2012 Jul 18
PMID 22802077
Citations 527
Authors
Affiliations
Soon will be listed here.
Abstract

High-throughput and high-content databases are increasingly important resources in molecular medicine, systems biology, and pharmacology. However, the information usually resides in unwieldy databases, limiting ready data analysis and integration. One resource that offers substantial potential for improvement in this regard is the NCI-60 cell line database compiled by the U.S. National Cancer Institute, which has been extensively characterized across numerous genomic and pharmacologic response platforms. In this report, we introduce a CellMiner (http://discover.nci.nih.gov/cellminer/) web application designed to improve the use of this extensive database. CellMiner tools allowed rapid data retrieval of transcripts for 22,379 genes and 360 microRNAs along with activity reports for 20,503 chemical compounds including 102 drugs approved by the U.S. Food and Drug Administration. Converting these differential levels into quantitative patterns across the NCI-60 clarified data organization and cross-comparisons using a novel pattern match tool. Data queries for potential relationships among parameters can be conducted in an iterative manner specific to user interests and expertise. Examples of the in silico discovery process afforded by CellMiner were provided for multidrug resistance analyses and doxorubicin activity; identification of colon-specific genes, microRNAs, and drugs; microRNAs related to the miR-17-92 cluster; and drug identification patterns matched to erlotinib, gefitinib, afatinib, and lapatinib. CellMiner greatly broadens applications of the extensive NCI-60 database for discovery by creating web-based processes that are rapid, flexible, and readily applied by users without bioinformatics expertise.

Citing Articles

Deciphering the role of CNIH4 in pan-cancer landscapes and its significance in breast cancer progression.

Xu Y, Lai Z, Li C Front Genet. 2025; 16:1536620.

PMID: 40051704 PMC: 11882561. DOI: 10.3389/fgene.2025.1536620.


ITGA4 as a potential prognostic and immunotherapeutic biomarker in human cancer and its clinical significance in gastric cancer: an integrated analysis and validation.

Zhang J, Wang G, Liu J, Tang F, Wang S, Li Y Front Oncol. 2025; 15:1513622.

PMID: 40012546 PMC: 11860100. DOI: 10.3389/fonc.2025.1513622.


The comprehensive potential of AQP1 as a tumor biomarker: evidence from kidney neoplasm cohorts, cell experiments and pan-cancer analysis.

Liu Y, Lyu D, Yao Y, Cui J, Liu J, Bai Z Hum Genomics. 2025; 19(1):15.

PMID: 39988693 PMC: 11849320. DOI: 10.1186/s40246-025-00726-9.


RECQ4-MUS81 interaction contributes to telomere maintenance with implications to Rothmund-Thomson syndrome.

Ashraf R, Polasek-Sedlackova H, Marini V, Prochazkova J, Hasanova Z, Zacpalova M Nat Commun. 2025; 16(1):1302.

PMID: 39900600 PMC: 11791078. DOI: 10.1038/s41467-025-56518-1.


Integrated Multi-omics Data Analysis and Validation Reveal the Crucial Role of Glycogen Metabolism in Gastric Cancer.

Zhou X, Wu J, Liu Y, Wang X, Gao X, Xia X J Cancer. 2025; 16(4):1243-1263.

PMID: 39895799 PMC: 11786036. DOI: 10.7150/jca.104424.


References
1.
Liu H, DAndrade P, Fulmer-Smentek S, Lorenzi P, Kohn K, Weinstein J . mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther. 2010; 9(5):1080-91. PMC: 2879615. DOI: 10.1158/1535-7163.MCT-09-0965. View

2.
Lorenzi P, Reinhold W, Varma S, Hutchinson A, Pommier Y, Chanock S . DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther. 2009; 8(4):713-24. PMC: 4020356. DOI: 10.1158/1535-7163.MCT-08-0921. View

3.
Nishizuka S, Chen S, Gwadry F, Alexander J, Major S, Scherf U . Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 2003; 63(17):5243-50. View

4.
Scherf U, Ross D, Waltham M, Smith L, Lee J, Tanabe L . A gene expression database for the molecular pharmacology of cancer. Nat Genet. 2000; 24(3):236-44. DOI: 10.1038/73439. View

5.
Tryndyak V, Beland F, Pogribny I . E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 2009; 126(11):2575-83. DOI: 10.1002/ijc.24972. View